GlassScriptPhysician profile
Daniel A D Andrea
NPI 1992763866
$3,838.02
in general payments reported to CMS, 2019-2025
16 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $76.66 · 2021: $199 · 2022: $211 · 2023: $961 · 2024: $874 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484 · Consulting Fee: $600 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.09 |
| Consulting Fee | $600.00 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $840.76 | 2019-2025 | Rexulti |
| Lundbeck LLC | $623.07 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $569.50 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $555.22 | 2022-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $343.59 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $338.72 | 2019-2025 | Trintellix |
| Abbvie INC. | $268.40 | 2021-2025 | |
| Bausch Health US, LLC | $98.08 | 2025 | Wellbutrin, Aplenzin |
| Allergan, INC. | $46.50 | 2020 | |
| Avanir Pharmaceuticals, INC. | $38.02 | 2022 | |
| Eisai INC. | $34.37 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $20.00 | 2019 | |
| Lilly USA, LLC | $17.93 | 2024 | Amyvid, Kisunla |
| Janssen Pharmaceuticals, INC | $15.34 | 2020 | |
| Alkermes, INC. | $14.93 | 2024 | Aristada, Lybalvi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.59 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel D Andrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.